Latest News and Press Releases
Want to stay updated on the latest news?
-
EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
-
EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
-
STOCKHOLM, SVERIGE – 8 januari 2026. Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) har den 8 januari 2026 hållit extra bolagsstämma, varvid aktieägarna beslutade...
-
STOCKHOLM, SWEDEN – January 8, 2026. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held an Extraordinary General Meeting on January 8, 2026, at which the shareholders...
-
STOCKHOLM, 22 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines AB har ingått en icke-bindande avsiktsförklaring med Novakand Pharma AB...
-
STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand...
-
STOCKHOLM, 11 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat nya prekliniska resultat för bolagets immunterapi SVF-001...
-
STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy...